NCT02112526View on ClinicalTrials.gov

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 7, 2014

Primary Completion Date

June 30, 2020

Study Completion Date

October 4, 2024

Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Interventions
DRUG

Acalabrutinib

Trial Locations (7)

10021

Research Site, New York

30322

Research Site, Atlanta

43210

Research Site, Columbus

77030

Research Site, Houston

90095

Research Site, Los Angeles

LE1 7RH

Research Site, Leicester

PL6 8DH

Research Site, Plymouth

Sponsors

Lead Sponsor

Acerta Pharma BV
All Listed Sponsors
lead

Acerta Pharma BV

INDUSTRY

NCT02112526 - Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter